RIL
CRSP icon

Rothschild Investment LLC’s CRISPR Therapeutics CRSP Stock Holding History

Rothschild Investment LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.33K Hold
61
– – ﹤0.01% 2508
2026
Q1 		$2.9K Sell
61
-501
-89% -$26.4K ﹤0.01% 2357
2025
Q4 		$29.5K Buy
562
+502
+837% +$30.1K ﹤0.01% 1190
2025
Q3 		$3.89K Hold
60
– – ﹤0.01% 1819
2025
Q2 		$2.92K Hold
60
– – ﹤0.01% 1807
2025
Q1 		$2.04K Hold
60
– – ﹤0.01% 1887
2024
Q4 		$2.36K Hold
60
– – ﹤0.01% 1709
2024
Q3 		$2.82K Hold
60
– – ﹤0.01% 1548
2024
Q2 		$3.24K Buy
60
+20
+50% +$1.16K ﹤0.01% 1271
2024
Q1 		$2.73K Buy
+40
New +$2.86K ﹤0.01% 1186

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Rothschild Investment LLC's CRSP Position: Q2 2026 in Review

Rothschild Investment LLC held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 61 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

Rothschild Investment LLC first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. The position peaked at $29.5K in Q4 2025. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Rothschild Investment LLC held 61 shares of CRISPR Therapeutics worth $3.33K as of Q2 2026.
  • Rothschild Investment LLC left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2508 holding.
  • Rothschild Investment LLC first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Rothschild Investment LLC's CRISPR Therapeutics position peaked at $29.5K in Q4 2025.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.